Summary
Amgen Inc. announced on July 27, 2021, that it has entered into an Agreement and Plan of Merger to acquire Teneobio, Inc. The acquisition involves an initial cash payment of $900 million at closing, with potential future contingent milestone payments totaling up to $1.6 billion. This strategic move is designed to enhance Amgen's pipeline, particularly in the area of bispecific antibody therapeutics, which are crucial for developing novel treatments for various diseases, including cancer. The transaction is subject to customary closing conditions, including regulatory approvals and the satisfaction of specific conditions related to Teneobio's corporate restructuring and the spin-off of certain subsidiaries. Notably, AbbVie will acquire TeneoOne, an affiliate of Teneobio, along with a specific antibody therapeutic. This acquisition underscores Amgen's commitment to expanding its therapeutic offerings through targeted M&A activities, aiming to bring innovative treatments to patients.
Key Highlights
- 1Amgen to acquire Teneobio, Inc. for an initial cash payment of $900 million.
- 2Potential for up to $1.6 billion in future contingent milestone payments.
- 3Teneobio's pipeline focuses on bispecific antibody therapeutics.
- 4Transaction includes customary representations, warranties, and indemnification provisions.
- 5Certain Teneobio subsidiaries will be spun out to Teneobio's equity holders prior to closing.
- 6AbbVie to acquire TeneoOne and a specific antibody therapeutic (TNB-383B) as part of the transaction's conditions.
- 7Closing is subject to customary conditions, including regulatory approvals and stockholder consents.